Clonal hematopoiesis of indeterminate potential and risk of immune thrombocytopenia
Journal of Internal Medicine · 2025-06 · 297 (6) · 672-682
DOI: 10.1111/joim.20092 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Internal Medicine, online erschienen am 29.04.2025. Verfasst von Qianwei Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China. Hauptthemen laut MEDLINE: Clonal Hematopoiesis, Purpura, Thrombocytopenic, Idiopathic. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 50 Literaturangaben.
Abstract (Originalsprache)
Background
Clonal hematopoiesis of indeterminate potential (CHIP) might contribute to the pathogenesis of immune thrombocytopenia (ITP) through immune dysfunction or impairment of megakaryopoiesis and platelet formation. However, little is known about subsequent risk of ITP among individuals with CHIP.
Objective
To investigate the risk of ITP among individuals with CHIP.
Methods
We investigated the association of CHIP with risk of ITP by a prospective cohort study, including 466,064 participants in the UK Biobank, during 2006 to 2022. CHIP was ascertained based on data of whole exome sequencing. Incident ITP was identified in inpatient hospital records and death register. Cox regression models were utilized to estimate risk of ITP associated with CHIP. We also performed subgroup analyses by CHIP mutations ( DNMT3A , TET2 , ASXL1 , SRSF2 , and JAK2 ).
Results
The study included 14,466 and 451,598 individuals with and without CHIP, respectively. We identified 34 and 390 cases of ITP among the CHIP group and the reference group, respectively. CHIP was associated with an increased risk of ITP (hazard ratio [HR] 2.33, 95% confidence interval [CI]: 1.64–3.32). Subgroup analysis revealed that the heightened risk of ITP was greatest in CHIP with JAK2 mutation (HR 54.31, 95% CI: 17.39–169.59), followed by CHIP with SRSF2 (HR 20.11, 95% CI: 8.27–48.87), TET2 (HR 4.00, 95% CI: 2.34–6.83), or DNMT3A (HR 1.95, 95% CI: 1.16–3.27) mutation.
Conclusion
CHIP was associated with an increased risk of being diagnosed with ITP, particularly for CHIP with JAK2 or SRSF2 mutation. These findings call for clinical awareness of the risk of ITP among individuals with CHIP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
- Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China.
- Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, and Department of Hematology, Karolinska University Hospital, Stockholm, Sweden.
- Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc…
ORCID-Profile: Tove Wästerlid, Karin E Smedby
Zitieren
APA
Liu, Q., Wästerlid, T., Smedby, K. E., Xue, H., Boberg, E., Fang, F., & Liu, X. (2025). Clonal hematopoiesis of indeterminate potential and risk of immune thrombocytopenia. Journal of Internal Medicine, 297(6), 672-682. https://doi.org/10.1111/joim.20092
Vancouver
Liu Q, Wästerlid T, Smedby KE, Xue H, Boberg E, Fang F, et al. Clonal hematopoiesis of indeterminate potential and risk of immune thrombocytopenia. Journal of Internal Medicine. 2025;297(6):672-682. doi:10.1111/joim.20092
BibTeX
@article{Liu2025,
author = {Liu, Qianwei and Wästerlid, Tove and Smedby, Karin E and Xue, Huiwen and Boberg, Erik and Fang, Fang and Liu, Xinyuan},
title = {Clonal hematopoiesis of indeterminate potential and risk of immune thrombocytopenia},
journal = {Journal of Internal Medicine},
year = {2025},
volume = {297},
number = {6},
pages = {672--682},
doi = {10.1111/joim.20092}
}
EUVIMED